2011


To access this material please log in or register

Register Authorize
2011/№3

Consensus of heart failure experts Society on application of highly selective aldosterone receptor blocker eplerenone in the treatment of chronic heart failure. Results of EPHESUS trial and EMPHASIS-HF substudy

VNOK, OSSN

Keywords:

DOI: 10.18087 / rhfj.2011.3.1530

  1. The CONSENSUS Trial Study Group. Effects of enalapril on morta­lity in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316 (23):1429–1435.
  2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325 (5):293–302.
  3. Pfeffer MA, Braunwald E, Moye LA et al, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327 (10):669–677.
  4. Jorde UP, Ennezat PV, Lisker J et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation. 2000;101 (8):844–846.
  5. Lee AF, MacFadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail. 1999;1 (4):401–406.
  6. Мареев В. Ю., Скворцов А. А., Челмакина С. М. и др. Способны ли ингибиторы АПФ эффективно контролировать активность ренин-ангиотензин-альдостероновой системы при длительном лечении хрониче­ской сердечной недостаточности? Кардиология. 1999;39 (2):27–34.
  7. Urata H, Healy BH, Stewart R et al. Angiotensin II forming pathways in normal and failing human hearts. Circ Res. 1990;66 (4):883–890.
  8. Golestaneh N, Klein C, Valamanesh F et al. Mineralocorticoid receptor-mediated signaling regulates the ion gated sodium channel in vascular endothelial cells and requires an intact cytoskeleton. Biochem Biophys Res Commun. 2001;280 (5):1300–1306.
  9. Agarwal MK, Mirshahi F, Mirshahi M, Rostene W. Immunochemical detection of mineralocorticoid receptor in rat brain. Neuroendocrinology. 1993;58 (5):575–580.
  10. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and rennin-angiotensin-aldosteron system. Circulation. 1991;83 (6):1849–1865.
  11. Farguharson CAJ, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in man: evidence for an aldosterone induced vascu­lopathy. Clin Sci (Lond). 2002;103 (4):425–431.
  12. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and rennin-angiotensin-aldosteron system. Circulation. 1991;83 (6):1849–1865.
  13. Hensen J, Abraham WT, Durr JA, Schrier RW. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. Am J Nephrol. 1991;11 (6):441–446.
  14. Dyckner T. Relation of cardiovascular disease to potassium and magnesium deficiencies. Am J Cardiol. 1990;65 (23):44K-46K.
  15. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82 (5):1730–1736.
  16. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341 (10):709–717.
  17. de Gasparo M, Joss U, Ramjoue HP et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987;240 (2):650–656.
  18. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15 (8):709–716.
  19. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348 (14):1309–1321.
  20. Pitt B, White H, Nicolau J et al; EPHESUS Investigators. Eplerenone reduced mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46 (3):425–431.
  21. Pitt B, Gheorghiade M, Zannad F et al; On behalf of the EPHESUS Investiga­tors. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30 %. Eur J Heart Fail. 2006;8 (3):295–301.
  22. Solomon SD, Zelenkofske S, McMurray JJ et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352 (25):2581–2588.
  23. Zannad F, McMurray JJ, Krum H et al. for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364 (1):11–21.
VNOK, OSSN. Consensus of heart failure experts Society on application of highly selective aldosterone receptor blocker eplerenone in the treatment of chronic heart failure. Results of EPHESUS trial and EMPHASIS-HF substudy. Russian Heart Failure Journal. 2011;12(3):177-179

To access this material please log in or register

Register Authorize
Ru En